Last reviewed · How we verify
Cholecalciferol 12 000 UI
Cholecalciferol (vitamin D3) is converted in the body to its active form, calcitriol, which regulates calcium and phosphate homeostasis and modulates immune function.
Cholecalciferol (vitamin D3) is converted in the body to its active form, calcitriol, which regulates calcium and phosphate homeostasis and modulates immune function. Used for Vitamin D deficiency, Hypocalcemia, Osteomalacia.
At a glance
| Generic name | Cholecalciferol 12 000 UI |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Vitamin D supplement |
| Target | Vitamin D receptor (VDR) |
| Modality | Small molecule |
| Therapeutic area | Nutritional deficiency / Bone health |
| Phase | FDA-approved |
Mechanism of action
Cholecalciferol is a fat-soluble vitamin that undergoes hydroxylation in the liver and kidneys to form the active hormone calcitriol (1,25-dihydroxyvitamin D3). The active metabolite binds to vitamin D receptors in the intestine, bone, and kidney to promote calcium absorption, maintain serum calcium and phosphate levels, and support bone mineralization. Additionally, calcitriol has immunomodulatory effects and regulates cell proliferation and differentiation.
Approved indications
- Vitamin D deficiency
- Hypocalcemia
- Osteomalacia
- Rickets
Common side effects
- Hypercalcemia
- Hypercalciuria
- Nausea
- Vomiting
- Constipation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cholecalciferol 12 000 UI CI brief — competitive landscape report
- Cholecalciferol 12 000 UI updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI